Advertisement

Evaluation and Management of Patients with Collagen Vascular Disease

  • Donald G. Payan
Chapter

Abstract

The clinical outcome of patients with the various manifestations of collagen vascular disease (CVD) has significantly improved over the past two decades with the increased use of diuretics, cytotoxic agents, dialysis, transplantation, and the judicious use of corticosteroids and other antiinflammatory agents directed at altering or delaying end-organ damage by the underlying immunopathologic process. A more rigorous definition of the various CVD clinical syndromes and a greater sophistication in the serologic, radiologic, and pathologic diagnostic methods have meant that patients with these diseases are now coming to clinical attention earlier in the course of their illness. Consequently, the physician is now encountering a greater number of clinical problems over a longer time span for each individual patient, rather than just the well-known complications of their end-stage disease. Despite the beneficial aspects of the newer therapeutic interventions to improve the clinical outcome of patients with CVD, the incidence of infection as a cause of both morbidity and mortality in these patients has not changed significantly over the past 30 years. A number of factors discussed in this chapter most likely contribute to the persistence of infectious complications in these patients. These include underlying host-defense abnormalities not significantly altered by therapeutic interventions, prolonged therapy with corticosteroids and alkylating agents that further suppress an already abnormal immune response, and an increased frequency of hospitalizations with more aggressive medical and surgical interventions, thereby increasing the risk of nosocomial infectious complications.

Keywords

Rheumatoid Arthritis Systemic Lupus Erythematosus Infectious Complication Septic Arthritis Adult Respiratory Distress Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Carpenter RC, Sturgill BC: The course of systemic lupus erythematosus. J. Chronic Dis 19: 117–131, 1966.PubMedGoogle Scholar
  2. 2.
    Dubois EL, Tuffanelli DL: Clinical manifestations of systemic lupus erythematosus: Computer analysis of the 520 cases. JAMA 190: 112–119, 1964.Google Scholar
  3. 3.
    Perez HD, Goldstein IM: Infection and host defenses in systemic lupus erythematosus. In Franklin EC (ed): Clinical Immunology Update. Amsterdam, Elsevier, 1979, pp 113–159.Google Scholar
  4. 4.
    Steinberg AD: Management of systemic lupus erythematosus. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 1098–1115.Google Scholar
  5. 5.
    Coplon NS, Diskin CJ, Petersen SJ, et al: The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 308: 186–190, 1983.PubMedGoogle Scholar
  6. 6.
    Cohen J, Pinching AJ: Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 51: 1–15, 1982.PubMedGoogle Scholar
  7. 7.
    Platt JL, Burke BA, Fish AJ, et al: Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 2(suppl 1): 212–222, 1982.PubMedGoogle Scholar
  8. 8.
    Rosner S, Ginzler EM, Diamond HS, et al: A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 6: 612–617, 1982.Google Scholar
  9. 9.
    Kiernan M, Bresnihan B: Clinical features and outcome of infection in systemic lupus erythematosus. Ir J Med Sci 152: 382–386, 1983.PubMedGoogle Scholar
  10. 10.
    Wallace DJ, Podell TE, Weiner JM, et al: Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 72: 209–220, 1982.PubMedGoogle Scholar
  11. 11.
    Hashimoto H, Shiokawa Y: Changing pattern of clinical features and prognosis in systemic lupus erythematosus. Scand J Rheumatol 7: 219–224, 1978.PubMedGoogle Scholar
  12. 12.
    Ginzler E, Diamond H, Kaplan D, et al: Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 21: 37–44, 1978.PubMedGoogle Scholar
  13. 13.
    Fish AJ, Blau EB, Westerberg NG, et al: Systemic lupus erythematosus within the first two decades of life. Am J Med 62: 99–117, 1977.PubMedGoogle Scholar
  14. 14.
    Urowitz MB, Bookman AA, Koehler BE, et al: The biomodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221–225, 1976.PubMedGoogle Scholar
  15. 15.
    Staples PG, Gerding DN, Decker JL, et al: Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 17: 1–10, 1974.PubMedGoogle Scholar
  16. 15a.
    Watanabe-Duffy KN, Duffy CM, Gladman DD: Infection and disease activity in systemic lupus erythematosus: A review of hospitalized patients. J Rheumatol 18: 1180–1184, 1991.Google Scholar
  17. 15b.
    Jonsson H, Nived O, Sturfelt G: Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine 68: 141–150, 1989.PubMedGoogle Scholar
  18. 15c.
    Lacks S, White P: Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol 17: 941–945, 1990.PubMedGoogle Scholar
  19. 16.
    Vandenbroucke JP, Hazevoet HM, Cats A: Survival and cause of death in rheumatoid arthritis: A 25-year prospective followup. J Rheumatol 11: 158–161, 1984.PubMedGoogle Scholar
  20. 17.
    Hollingsworth JW, Saykaly RJ: Systemic complications of rheumatoid arthritis. Med Clin North Am 61: 217–228, 1977.PubMedGoogle Scholar
  21. 18.
    Prior P, Symmons DP, Scott DL, et al: Cause of death in rheumatoid arthritis. Br J Rheumatol 23: 92–99, 1984.PubMedGoogle Scholar
  22. 19.
    Lee P, Urowitz MB, Bookman AAM, et al: Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aspectic necrosis and prognosis, Q J Med 181: 1–32, 1977.Google Scholar
  23. 20.
    Rothfield N: Clinical features of systemic lupus erythematosus. In Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 1870–1907.Google Scholar
  24. 21.
    Harris ED Jr: Rheumatoid arthritis: The clinical spectrum. In Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 915–950.Google Scholar
  25. 22.
    Myers AR: Septic arthritis caused by bacteria, in Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 1507–1527.Google Scholar
  26. 23.
    Schnitzer TJ: Viral arthritis. In Kelly WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 1540–1556.Google Scholar
  27. 24.
    Benson CH, Harisdangkul V: Disseminated gonococcal infection in systemic lupus erythematosus. (Letter.) J Rheumatol 10: 668–669, 1983.PubMedGoogle Scholar
  28. 25.
    Churchill MA, Geraci JE, Hunder GG: Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 87: 754–757, 1977.PubMedGoogle Scholar
  29. 26.
    Ellis SG, Verity MA: Central nervous system involvement in systemic lupus erythematosus: A review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8: 212–221, 1979.PubMedGoogle Scholar
  30. 27.
    Johnson R, Richardson E: The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 47: 1399–1402, 1968.Google Scholar
  31. 28.
    Schur PH: Systemic lupus erythematosus. In Wyngaarden JB, Smith LH Jr (eds): Cecil Textbook of Medicine. Philadelphia, WB Saunders, 1982, pp 1852–1857.Google Scholar
  32. 29.
    Mitchell WS, Brooks PM, Stevenson RD, et al: Septic arthritis in patients with rheumatoid disease: A still underdiagnosed complication. J Rheumatol 3: 124–133, 1976.PubMedGoogle Scholar
  33. 29a.
    van Albada-Kuipers GA, Linthorst J, Peeters EAJ, et al: Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 31: 667–671, 1988.PubMedGoogle Scholar
  34. 30.
    Huskisson EC, Hart FD: Severe, unusual, and recurrent infections in rheumatoid arthritis. Ann Rheum Dis 31: 118–121, 1972.PubMedGoogle Scholar
  35. 31.
    Walker WC: Pulmonary infections and rheumatoid arthritis. Q J Med 36: 239–251, 1967.PubMedGoogle Scholar
  36. 32.
    Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosus. Arch Pathol Lab Med 32: 569–631, 1941.Google Scholar
  37. 33.
    Ropes MW: Observations on the natural course of disseminated lupus erythematosus. Medicine (Baltimore) 43: 387–391, 1964.Google Scholar
  38. 34.
    Dubois EL, Wierzchowiecki M, Cox MB, et al: Duration and death in systemic lupus erythematosus: An analysis of 249 cases. JAMA 227: 1399–1402, 1974.PubMedGoogle Scholar
  39. 35.
    Harvey AM, Shulman LE, Tumulty PA, et al: Systemic lupus erythematosus: Review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 33: 291–437, 1954.Google Scholar
  40. 36.
    Estes D, Christian CL: The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 50: 85–95, 1971.Google Scholar
  41. 37.
    Hashimoto H, Shiokawa Y: Changing pattern of clinical features and prognosis in systemic lupus erythematosus. Scand J Rheumatol 7: 219–224, 1978.PubMedGoogle Scholar
  42. 38.
    Allebeck P: Increased mortality in rheumatoid arthritis. Scand J Rheumatol 11: 81–86, 1982.PubMedGoogle Scholar
  43. 39.
    Koota K, Isomaki H, Mutra O: Death rate and causes of death in RA patients during a period of five years. Scand J Rheumatol 6: 241–244, 1977.PubMedGoogle Scholar
  44. 40.
    Mutra O, Koota K, Isomaki H: Causes of death in autopsied RA patients. Scand J Rheumatol 5: 239–240, 1976.Google Scholar
  45. 41.
    Cosh JA: Survival and death in rheumatoid arthritis. J Rheum 11: 117–118, 1984.PubMedGoogle Scholar
  46. 42.
    Zvaifler NJ, Woods VL Jr: Etiology and pathogenesis of systemic lupus erythematosus. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 1042–1070.Google Scholar
  47. 43.
    Bennett JC: The etiology of rheumatoid arthritis. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 879–886.Google Scholar
  48. 44.
    Harris ED Jr: Pathogenesis of rheumatoid arthritis. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 886–915.Google Scholar
  49. 45.
    Johnson RB, Stroud RM: Complement and host defense against infection. J Pediatr 90: 169–179, 1977.Google Scholar
  50. 46.
    Muller-Eberhard HJ: Complement. Annu Rev Biochem 44: 697–724, 1975.PubMedGoogle Scholar
  51. 47.
    Shur PH: Complement in lupus. Clin Rheum Dis 1: 519–524, 1975.Google Scholar
  52. 48.
    Kaplan RA, Curd JG, DeHeer DH, et al: Metabolism of C4 and factor B in rheumatoid arthritis: Relation to rheumatoid factor. Arthritis Rheum 23: 911–924, 1980.PubMedGoogle Scholar
  53. 49.
    Kohler PF, Ten Beusel R: Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus. Clin Exp Immunol 4: 1901–1922, 1969.Google Scholar
  54. 50.
    Jasin HE, Ziff M: Immunoglobulin synthesis by peripheral blood cells in systemic lupus erythematosus. Arthritis Rheum 18: 219–228, 1975.PubMedGoogle Scholar
  55. 51.
    McLean RH, Michael AF: Properdin and C3 proactivator: Alternate pathway components in human glomerulonephritis. J Clin Invest 52: 634–644, 1973.PubMedGoogle Scholar
  56. 52.
    Schur PH, Sandson J: Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278: 533–535, 1968.PubMedGoogle Scholar
  57. 53.
    Ellis HA, Felix-Davies D: Serum complement, rheumatoid factor, and other serum proteins in rheumatoid disease and systemic lupus erythematosus. Ann Rheum Dis 18: 215–244, 1959.PubMedGoogle Scholar
  58. 54.
    Ross SC, Densen P: Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63: 243–273, 1984.Google Scholar
  59. 55.
    Jazin HE, Orozco JH, Ziff M: Serum heat-labile opsonins in systemic lupus erythematosus. J Clin Invest 53: 343–353, 1974.Google Scholar
  60. 55a.
    Mitchell SR, Nguyen PG, Katz P: Increased risk of neisserial infections in systemic lupus erythematosus. Semin Arthritis Rheum 20: 174–184, 1990.PubMedGoogle Scholar
  61. 56.
    Louis JS, Nies KM, Shoji KT, et al: Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 88: 790–792, 1978.Google Scholar
  62. 57.
    Williams GW, Steinberg AD, Reinertsen JL, et al: Influenza immunization in systemic lupus erythematosus. Ann Intern Med 88: 729–734, 1978.PubMedGoogle Scholar
  63. 58.
    Hess EV: Influenza immunization in systemic lupus erythematosus: Safe, effective?. Ann Intern Med 88: 833–834, 1978.PubMedGoogle Scholar
  64. 59.
    Meiselas LE, Zingale SB, Lee SL, et al: Antibody production in rheumatic diseases: The effect of Brucella antigen. J Clin Invest 40: 1872–1881, 1961.PubMedGoogle Scholar
  65. 60.
    Baum J, Ziff M: Decreased 19S antibody response to bacterial antigens in systemic lupus erythematosus. J Clin Invest 487: 758–767, 1969.Google Scholar
  66. 61.
    Messner RP, DeHoratius RJ: Epidemiology of antilymphocyte antibodies in systemic lupus erythematosus. Arthritis Rheum 21: S167–169, 1978.PubMedGoogle Scholar
  67. 62.
    Bluestein HG: Autoantibodies to lymphocyte membrane antigens: Pathogenetic implications. Clin Rheum Dis 4: 643–647, 1978.Google Scholar
  68. 63.
    Winfield JB, Cohen PL, Litvin DA: Antibodies to activated cells and their soluble products in systemic lupus erythematosus. Arthritis Rheum 25: 814–819, 1982.PubMedGoogle Scholar
  69. 64.
    Clark RA, Kimball HR, Decker JL: Neutrophil chemotaxis in systemic lupus erythematosus. Ann Rheum Dis 33: 167–172, 1974.PubMedGoogle Scholar
  70. 65.
    Goetzl EJ: Defective responsiveness to ascorbic acid of neutrophil random and chemotactic migration in Felty’s syndrome and systemic lupus erythematosus. Ann Rheum Dis 35: 510–515, 1976.PubMedGoogle Scholar
  71. 66.
    Perez HD, Lipton M, Goldstein IM: A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest 62: 29–38, 1978.PubMedGoogle Scholar
  72. 67.
    Perez HD, Andron RI, Goldstein IM: Infection in patients with systemic lupus erythematosus. Association with a serum inhibitor of complement-derived chemotactic activity. Arthritis Rheum 22: 1326–1333, 1979.PubMedGoogle Scholar
  73. 68.
    Brandt L, Hedberg H: Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. Scand J Haematol 6: 348–353, 1969.PubMedGoogle Scholar
  74. 69.
    Wenger ME, Bole GG: Nitroblue tetrazolium dye reduction by peripheral leukocytes from rheumatoid arthritis and systemic lupus erythematosus patients measured by a histochemical and spectrophotometric method. J Lab Clin Med 82: 513–521, 1973.PubMedGoogle Scholar
  75. 70.
    Karnovsky ML: The metabolism of leukocytes. Semin Hematol 5: 156–165, 1968.PubMedGoogle Scholar
  76. 71.
    McLeod R, Wing EJ, Remington JS: Lymphocytes and macrophages in cell-mediated immunity. In Mandell GL, Douglas RG, Bennett JE (eds): Principles and Practice of Infectious Diseases. New York, Wiley, 1985, pp 72–93.Google Scholar
  77. 72.
    Hahn BH, Bagby MK, Osterland CK: Abnormalities of delayed hypersensitivity in systemic lupus erythematosus. Am J Med 55: 25–30, 1973.PubMedGoogle Scholar
  78. 73.
    Rosenthal CJ, Franklin DC: Depression of cellular-mediated immunity in systemic lupus erythematosus. Arthritis Rheum 18: 208–212, 1975.Google Scholar
  79. 74.
    Horowitz DA: Impaired delayed hypersensitivity in systemic lupus erythematosus. Arthritis Rheum 15: 353–355, 1972.Google Scholar
  80. 75.
    Sakane T, Steinberg AD, Green I: Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 75: 3464–3467, 1978.PubMedGoogle Scholar
  81. 76.
    Smolen JS, Chused TM, Leiserson WM, et al: Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med 72: 783–786, 1982.PubMedGoogle Scholar
  82. 77.
    Ginsberg WW, Finkelman FD, Lipsky PE: Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. Clin Exp Immunol. 35: 76–80, 1979.Google Scholar
  83. 78.
    Sagawa A, Abdou NI: Suppressor-cell dysfunction in systemic lupus erythematosus: Cells involved and in vitro correction. J Clin Invest 62: 789–794, 1978.PubMedGoogle Scholar
  84. 79.
    Katz P, Zaytoun AM, Lee JH Jr, et al: Abnormal natural killer cell activity in systemic lupus erythematosus: An intrinsic defect in the lytic event. J Immunol 129: 1966–1970, 1982.PubMedGoogle Scholar
  85. 80.
    Hasler F, Bluestein HG, Zvaifler NJ, et al: Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation J Exp Med 157: 173–179, 1983.PubMedGoogle Scholar
  86. 81.
    Trentham DE, Dynesius RA, Rocklin RE, et al: Cellular sensitivity to collagen in rheumatoid arthritis. N Engl J Med 299: 311–327, 1978.Google Scholar
  87. 82.
    Dohlong JH, Forre O, Kvien TK, et al: Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis. Ann Rheum Dis 41: 490–494, 1982.Google Scholar
  88. 83.
    Parillo JE, Fauci AS: Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 19: 179–191, 1979.Google Scholar
  89. 84.
    Axelrod L: Glucocorticoids. In Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, WB Saunders, 1985, pp 815–832.Google Scholar
  90. 85.
    Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 84: 304–315, 1976.PubMedGoogle Scholar
  91. 86.
    Bovornkitti S, Kangsadal P, Sathirpat P, et al: Reversion and reconversion rate of tuberculin skin reactions in correlation with the use of prednisone. Dis Chest 38: 51–55, 1960.PubMedGoogle Scholar
  92. 87.
    Balow JE, Rosenthal AS: Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med 137: 1031–1042, 1973.PubMedGoogle Scholar
  93. 88.
    DeSousa M, Fachet J: The cellular basis of the mechanism of action of cortisone acetate on contact sensitivity to oxazolone in the mouse, Clin Exp Immunol 10: 673–684, 1972.Google Scholar
  94. 89.
    Reinehart JJ, Sagone AL, Balcerzak SP: Effects of corticosteroid therapy on human monocyte function. N Engl J Med 292: 236–241, 1975.Google Scholar
  95. 90.
    Fauci AS, Dale DC: The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 53: 240–246, 1974.PubMedGoogle Scholar
  96. 91.
    Stavy L, Cohen IR, Feldman M: The effect of hydrocortisone on lymphocyte-mediated cytolysis. Cell Immunol 7: 302–312, 1973.PubMedGoogle Scholar
  97. 92.
    Bishop CR, Athens JW, Boggs DR, et al: Leukokinetic studies XIII: A non steady-state kinetic evaluation of the mechanisms of cortisone-induced granulocytosis. J Clin Invest 47: 249–261, 1968.PubMedGoogle Scholar
  98. 93.
    Butler WT, Rossen RD: Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methyl prednisolone. J Clin Invest 52: 2629–2640, 1973.PubMedGoogle Scholar
  99. 94.
    Atkinson JP, Frank MM: Effects of cortisone therapy on serum complement components. J Immunol 111: 1061–1066, 1973.PubMedGoogle Scholar
  100. 95.
    Robinson DR, Tashjian AH Jr, Levine L: Prostaglandin-stimulated bone resorption by rheumatoid synovia; A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 56: 1181–1189, 1975.PubMedGoogle Scholar
  101. 96.
    Samuelsson B: Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568–572, 1983.PubMedGoogle Scholar
  102. 97.
    Shand FL: The immunopharmacology of cyclophosphamide. Int J Pharmacol 1: 165–180, 1979.Google Scholar
  103. 98.
    Decker JL: Toxicity of immunosuppressive drugs in man. Arthritis Rheum 16: 89–101, 1973.PubMedGoogle Scholar
  104. 99.
    Cupps TR, Edgar LC, Fauci AS: Suppression of human B lymphocyte function by cyclophosphamide J Immunol 128: 2453–2457, 1982.PubMedGoogle Scholar
  105. 100.
    Hurd ER, Giuliano VJ: The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. Arthritis Rheum 18: 67–75, 1975.PubMedGoogle Scholar
  106. 101.
    Askenase PW, Hayden BJ, Gershon RK: Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not effect antibody responses. J Exp Med 141: 697–703, 1975.PubMedGoogle Scholar
  107. 102.
    Yu DT, Clements PJ, Peter JB, et al: Lymphocyte characteristics in rheumatic patients and the effects of azathioprine therapy. Arthritis Rheum 17: 37–43, 1974.Google Scholar
  108. 103.
    Maibach HI, Epstein WL: Immunologic responses of healthy volunteers receiving azathioprine (Imuran). Int Arch Allergy 27: 102–107, 1965.PubMedGoogle Scholar
  109. 104.
    Fournier C, Bach MA, Dardenne M, et al: Selective action of azathioprine on T cells. Transplant Proc 5: 523–527, 1973.PubMedGoogle Scholar
  110. 105.
    Gassman AE, vanFurth R: The effects of azathioprine on the kinetics of monocytes and macrophages during the normalsteady state and an acute inflammatory reaction. Blood 46: 51–59, 1975.Google Scholar
  111. 106.
    Levy J, Barnett EV, MacDonald NS, et al: The effect of azathioprine on gammaglobulin synthesis in man. J Clin Invest 51: 2233–2238, 1972.PubMedGoogle Scholar
  112. 107.
    Schultz DR, Volanakis JE, Arnold PI, et al: Inactivation of C1 in rheumatoid synovial fluid, purified C1 and C1 esterase, by gold compounds. Clin Exp Immunol 17: 395–401, 1974.PubMedGoogle Scholar
  113. 108.
    Paltemaa S: The inhibition of lysosomal enzymes by gold salts in human synovial fluid cells. Acta Rheumatol Scand 14: 161–165, 1968.PubMedGoogle Scholar
  114. 109.
    Penneys NS, Ziboh V, Gottlieb NL, et al: Inhibition of prostaglandin synthesis and human epidermal enzymes by aurothiomalate in vitro: Possible actions of gold in pemphigus. J Invest Dermatol 63: 356–361, 1974.PubMedGoogle Scholar
  115. 110.
    Jessop JE, Vernon-Roberts B, Harris, J: Effects of gold salts and prednisolone in inflammatory cells. Ann Rheum Dis 32: 294–301, 1973.PubMedGoogle Scholar
  116. 111.
    Lies RB, Cardin C, Paulus HE: Inhibition by gold of human lymphocyte stimulation. Ann Rheum Dis 36: 216–220, 1977.PubMedGoogle Scholar
  117. 112.
    Cohen J, Pinching AJ, Rees AJ, et al: Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 51: 1–15, 1982.PubMedGoogle Scholar
  118. 113.
    Hashimoto H, Maekawa S, Nasu H, et al: Systemic vascular lesions and prognosis in systemic lupus erythematosus. Scand J Rheumatol 13: 45–55, 1984.PubMedGoogle Scholar
  119. 114.
    Baum J: Infection and rheumatoid arthritis. Arthritis Rheum 14: 135–137, 1971.PubMedGoogle Scholar
  120. 115.
    Poss R, Thornhill TS, Ewald FC, et al: Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop 182: 117–126, 1984.PubMedGoogle Scholar
  121. 116.
    Stahl NI, Klippel JH, Decker JL: Fever in systemic lupus erythematosus. Am J Med 67: 935–940, 1979.PubMedGoogle Scholar
  122. 116a.
    ter Borg EJ, Horst G, Limburg PC, et al: C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study. J Rheumatol 17: 1642–1648, 1990.PubMedGoogle Scholar
  123. 116b.
    Tokano Y, Tagita H, Iida N, et al: Relation between the level of IgG subclasses and infections in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol 87: 55–58, 1988.PubMedGoogle Scholar
  124. 116c.
    Feinglass EJ, Arnett FC, Dorsch CA, et al: Neuropsychiatric manifestations of systemic lupus erythematosus. Diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 55: 323–339, 1976.Google Scholar
  125. 116d.
    Schwartz B, Glazer H, Williams E: Clinicopathologic conference: Headache, mental status changes, and death in a 36-year-old woman with lupus. Am J Med 86: 94–102, 1989.Google Scholar
  126. 117.
    Siekert RG, Clark EC: Neurologic signs and symptoms as early manifestations of SLE. Neurology (NY) 5: 84–88, 1955.Google Scholar
  127. 118.
    Feinglass EJ, Arnett FC, Dorsch CA, et al: Neuropsychiatric manifestations of SLE: Diagnosis, clinical spectrum and relationship to other features of the disease. Medicine (Baltimore) 55: 323–339, 1976.Google Scholar
  128. 119.
    Reintz E, Hubbard D, Grayzel AI: Central nervous system systemic lupus erythematosus versus central nervous system infection: Low cerebral spinal fluid glucose and pleocytosis in a patient with a prolonged course. Arthritis Rheum 25: 583–588, 1982.Google Scholar
  129. 120.
    Gibson T, Myers AR: Nervous system involvement in SLE. Ann Rheum Dis 35: 398–406, 1976.Google Scholar
  130. 121.
    Andrianakos AA, Duffy J, Suzuki M, et al: Transverse myelopathy in SLE. Ann Intern Med 83: 616–624, 1975.PubMedGoogle Scholar
  131. 122.
    Collins JV, Tong D, Bucknall RG, et al: Cryptococcal meningitis as a complication of systemic lupus erythematosus treated with systemic corticosteroids. Postgrad Med J 48: 52–55, 1972.PubMedGoogle Scholar
  132. 123.
    Sieving RR, Kaufman CA, Watanakunakor C: Deep fungal infection in systemic lupus erythematosus: Three cases reported, literature reviewed. J Rheumatol 2: 61–72, 1975.PubMedGoogle Scholar
  133. 124.
    Bennett J, Dismukes W, Duma R, et al: A collaborative trial of flucytosine-amphotericin B and amphotericin B alone in cryptococcal meningitis. N Engl J Med 301: 126–130, 1979.PubMedGoogle Scholar
  134. 125.
    Diamond RD, Bennett JE: Prognostic factors in cryptococcal meningitis. A study of 111 cases. Ann Intern Med. 80: 176–181, 1974.PubMedGoogle Scholar
  135. 126.
    Matthay RA, Schwarz MI, Petty TL, et al: Pulmonary manifestations of systemic lupus erythematosus: Review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 54: 397–409, 1974.Google Scholar
  136. 127.
    Haupt HM, Moore GW, Hutchins GM: The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 71: 791–798, 1981.PubMedGoogle Scholar
  137. 128.
    Matthay RA, Schwarz MI, Petty TL: Pleuro-pulmonary manifestations of connective tissue diseases. Clin Notes Respir Dis 16: 3–9, 1977.PubMedGoogle Scholar
  138. 129.
    Hunninghake GW, Fauci AS: Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 119: 471–503, 1979.PubMedGoogle Scholar
  139. 130.
    Israel HL: The pulmonary manifestations of disseminated lupus erythematosus. Am J Med Sci 226: 387–392, 1953.PubMedGoogle Scholar
  140. 131.
    Webb WR, Gamsu G: Cavitary pulmonary nodules with systemic lupus erythematosus: Differential diagnosis. Am J Radiol 136: 27–31, 1981.Google Scholar
  141. 132.
    Eagen JW, Memoli VA, Roberts JL: Pulmonary hemorrhage in systemic lupus erythematosus. Medicine (Baltimore) 57: 545–560, 1978.Google Scholar
  142. 133.
    Feng PH, Tan TH: Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis 41: 11–14, 1982.PubMedGoogle Scholar
  143. 134.
    Millar JW, Home NW: Tuberculosis in immunosuppressed patients. Lancet 1: 1176–1178, 1982.Google Scholar
  144. 135.
    Palmer DL, Harvey RL, Wheeler JK: Diagnostic and therapeutic considerations in Nocardia asteroides infection. Medicine (Baltimore) 53: 391–401, 1974.Google Scholar
  145. 136.
    Gorevic PD, Katler El, Argus B: Pulmonary nocardiosis. Occurrence in men with systemic lupus erythematosus. Arch Intern Med 140: 361–364, 1980.PubMedGoogle Scholar
  146. 137.
    O’Neill PB: Gastrointestinal abnormalities in the collagen diseases. Am J Dig Dis 6: 1069–1085, 1961.PubMedGoogle Scholar
  147. 138.
    Hoffman BI, Katz WA: The gastrointestinal manifestations of systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum 9: 237–247, 1980.PubMedGoogle Scholar
  148. 139.
    Zizic TM, Classen JN, Stevens MB: Acute abdominal complications of systemic lupus erythematosus and polyarteritis nodosa. Am J Med 73: 525–531, 1982.PubMedGoogle Scholar
  149. 140.
    Pollack VE, Grove WJ, Kark RM, et al: Systemic lupus erythematosus stimulating acute surgical condition of the abdomen. N Engl J Med 259: 258–266, 1958.Google Scholar
  150. 141.
    Reynolds J: Acute pancreatitis in systemic lupus erythematosus: Report of 20 cases and review of the literature. Medicine (Baltimore) 61: 25–32, 1982).Google Scholar
  151. 142.
    Lipsky PE, Hardin JA, Schour L, et al: Spontaneous peritonitis and systemic lupus erythematosus. JAMA 232: 929–931, 1975.PubMedGoogle Scholar
  152. 143.
    Seinknecht CW, Urowitz MB, Pruzanski W, et al: Felty’s syndrome: Clinic and serologic analysis of 34 cases. Ann Rheum Dis 36: 500–507, 1977.Google Scholar
  153. 144.
    Ortbals DW, Marr JJ: A comparative study of tuberculosis and other mycobacterial infections and their association with malignancy. Am Rev Respir Dis 117: 39–45, 1978.PubMedGoogle Scholar
  154. 145.
    DeMerieux PA, Keystone EC, Hutcheon M, et al: Polyarthritis due to Mycobacterium kansasii in a patient with rheumatoid arthritis. Ann Rheum Dis 39: 90–94, 1980.PubMedGoogle Scholar
  155. 146.
    Hoffman GS, Myers, RL, Stark FR, et al: Septic arthritis associated with Mycobacterium avium: A case report and literature review. J Rheum 5: 199–209, 1978.PubMedGoogle Scholar
  156. 147.
    Quismorio FP, Dubois EL: Septic arthritis in systemic lupus erythematosus. J Rheum 2: 73–82, 1975.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • Donald G. Payan
    • 1
  1. 1.Division of Infectious DiseasesUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations